Endotoxin removal devices for the treatment of sepsis and septic shock

The Lancet Infectious Diseases

Volumn 11, Issue 1, 2011, Pages 65-71

  Davies, B ^a   Cohen, J ^a  

^a BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADSORBENT; DIETHYLAMINOETHYL CELLULOSE; ENDOTOXIN; LIPOPOLYSACCHARIDE; POLYMYXIN; POLYMYXIN B;

ADSORPTION; ANTIMICROBIAL ACTIVITY; DEVICE; DRUG BINDING; HEMOPERFUSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK;

BLOOD CHEMICAL ANALYSIS; ENDOTOXINS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HEMOPERFUSION; HUMANS; ITALY; JAPAN; POLYMYXINS; SHOCK, SEPTIC;

EID: 78650233801     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(10)70220-6     Document Type: Review

References (71)

1. Daniels R Incidence, mortality and economic burden of sepsis. NHS Evidence (accessed Oct 13, 2010). http://www.library.nhs.uk/Emergency/ViewResource.aspx?resID=269230.
2. Harrison DA, Welch CA, Eddleston JM The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit Care 2006, 10:R42.
3. Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006, 34:344-353.
4. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302:2323-2329.
5. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
6. Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005, 353:1332-1341.
7. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock [published erratum in Crit Care Med 2008; 36: 1394-96]. Crit Care Med 2008, 36:296-327.
8. Shimazu R, Akashi S, Ogata H, et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999, 189:1777-1782.
9. Aderem A, Ulevitch RJ Toll-like receptors in the induction of the innate immune response. Nature 2000, 406:782-787.
10. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in TLR4 gene. Science 1998, 282:2085-2088.
11. Dunn DL, Priest BP, Condie RM Protective capacity of polyclonal and monoclonal antibodies directed against endotoxin during experimental sepsis. Arch Surg 1988, 123:1389-1393.
12. Appelmelk BJ, Cohen J The protective role of antibodies to the lipopolysaccharide core region. Bacterial endotoxin lipopolysaccharides. Vol 2. Immunopharmacology and pathophysiology 1992, 375-410. CRC Press, Boca Raton. J.L. Ryan, D.C. Morrison (Eds.).
13. van Deventer SJ, Buller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990, 76:2520-2526.
14. da Silva AM Taveira, Kaulbach HC, Chuidian FS, Lambert DR, Suffredini AF, Danner RL Shock and multiple organ dysfunction after self-administration of Salmonella endotoxin. N Engl J Med 1993, 328:1457-1460.
15. Marshall JC, Foster D, Vincent JL, et al. Diagnostic and prognostic implications of endotoxaemia in critical illness. Results of the MEDIC trial. J Infect Dis 2004, 190:527-534.
16. Brandtzaeg P, Kerrulf P, Gaustad P, et al. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. Lancet 1989, 159:195-204.
17. Opal SM, Scannon PJ, Vincent JL Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 1999, 180:1584-1589.
18. Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis 2006, 6:589-601.
19. Vaara M, Fox J, Loidl G, et al. Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. Antimicrob Agents Chemother 2008, 52:3229-3236.
20. Bhor VM, Thomas CJ, Surolia N, Surolia A Polymyxin B: an ode to an old antidote for endotoxic shock. Mol Biosyst 2005, 1:213-222.
21. Thomas CJ, Gangadhar BP, Surolia N, Surolia A Kinetics and mechanism of the recognition of endotoxin by Polymyxin B. J Am Chem Soc 1998, 120:12428-12434.
22. Srimal S, Surolia N, Balasubramanian S, Surolia A Titration calorimetric studies to elucidate the specificity of the interactions of polymyxin B with lipopolysaccharides and lipid A. Biochem J 1996, 315:679-686.
23. Rifkind D, Palmer JD Neutralization of endotoxin toxicity in chick embryos by antibiotics. J Bacteriol 1966, 92:815-819.
24. Rifkind D Prevention by polymyxin B of endotoxin lethality in mice. J Bacteriol 1967, 93:1463-1464.
25. From AH, Fong JS, Good RA Polymyxin B sulfate modification of bacterial endotoxin: effects on the development of endotoxin shock in dogs. Infect Immun 1979, 23:660-664.
26. Hughes B, Madan BR, Parratt JR Polymyxin B sulphate protects cats against the haemodynamic and metabolic effects of E coli endotoxin. Br J Pharmacol 1981, 74:701-707.
27. Hanasawa K, Tani T, Oka T, et al. A new treatment for endotoxemia with direct hemoperfusion by polymyxin immobilized fiber. Ther Apher 2000, 4:142-145.
28. Bannatyne RM, Cheung R Protective effect of polymyxin B sulfate in experimental enterobacterial infection in mice. Can J Microbiol 1979, 25:995-998.
29. Hirayama C, Sakata M Chromatographic removal of endotoxin from protein solutions by polymer particles. J Chromatogr B Analyt Technol Biomed Life Sci 2002, 781:419-432.
30. Nolan JP, McDevitt JJ, Goldmann GS, Bishop C Endotoxin binding by charged and uncharged resins. Proc Soc Exp Biol Med 1975, 149:766-770.
31. Morrison DC, Jacobs DM Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry 1976, 13:813-818.
32. Issekutz AC Removal of gram negative endotoxin from solutions by affinity chromatography. J Immunol Methods 1983, 61:275-281.
33. Cohen J, Aslam M, Pusey CD, Ryan CJ Protection from endotoxemia: a rat model of plasmapheresis and specific adsorption with polymyxin B. J Infect Dis 1987, 155:690-695.
34. Shoji H Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial 2003, 7:108-114.
35. Tani T, Hanasawa K, Endo Y, et al. Therapeutic apheresis for septic patients with organ dysfunction: hemoperfusion using a polymyxin B immobilized column. Artif Organs 1998, 22:1038-1044.
36. Aoki H, Kodama M, Tani T, Hanasawa K Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilised fiber. Am J Surg 1994, 167:412-417.
37. Kodama M, Tani T, Hanasawa K, et al. Treatment of sepsis by plasma endotoxin removal: hemoperfusion using a polymyxin-B immobilized column. J Endotoxin Res 1997, 4:293-300.
38. Sakamoto Y, Mashiko K, Obata T, et al. Relationship between treatment resistance to hemoperfusion using a polymyxin B-immobilised fiber column and oxidative stress. ASAIO J 2008, 54:412-415.
39. Uriu K, Osajima A, Hiroshige K, et al. Endotoxin removal by direct hemoperfusion with an adsorbent column using polymyxin B-immobilised fiber ameliorates systemic circulatory disturbance in patients with septic shock. Am J Kidney Dis 2002, 39:937-947.
40. Kodama M, Hanasawa K, Tani T Blood purification for critical care medicine: endotoxin adsorption. Ther Apher 1997, 1:224-227.
41. Kase Y, Obata T, Okamoto Y, et al. Removal of 2-arachidonylglycerol by direct hemoperfusion therapy with polymyxin B immobilized fibers benefits patients with septic shock. Ther Apher Dial 2008, 12:374-380.
42. Cantaluppi V, Assenzio B, Pasero D, et al. Polymyxin-B hemoperfusion inactivates circulating proapoptotic factors. Intensive Care Med 2008, 34:1638-1645.
43. Kohro S, Imaizumi H, Yamakage M, et al. Anandamide absorption by direct hemoperfusion with polymixin B-immobilized fiber improves the prognosis and organ failure assessment score in patients with sepsis. J Anesth 2006, 20:11-16.
44. Vincent JL, Laterre PF, Cohen J, et al. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 2005, 23:400-405.
45. Matsuno N, Ikeda T, Hama K, et al. Changes of cytokines in direct endotoxin adsorption treatment on postoperative multiple organ failure. Ther Apher 2001, 5:36-39.
46. Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009, 301:2445-2452.
47. Vincent JL Polymyxin B hemoperfusion and mortality in abdominal septic shock. JAMA 2009, 302:1968.
48. Amaral AC Polymyxin B hemoperfusion and mortality in abdominal septic shock. JAMA 2009, 302:1968-1969.
49. Safety and efficacy of polymyxin B hemoperfusion (PMX) for septic shock (EUPHRATES). NCT01046669. (accessed Oct 13, 2010). http://clinicaltrials.gov/ct2/show/NCT01046669.
50. Martin EL, Cruz DN, Monti G, et al. Endotoxin removal: how far from the evidence? The EUPHAS 2 Project. Contrib Nephrol 2010, 167:119-125.
51. Kojika M, Sato N, Yaegashi Y, et al. Endotoxin adsorption therapy for septic shock using polymyxin B-immobilized fibers (PMX): evaluation by high-sensitivity endotoxin assay and measurement of the cytokine production capacity. Ther Apher Dial 2006, 10:12-18.
52. Tani T, Hanasawa K, Kodama M, et al. Correlation between plasma endotoxin, plasma cytokines, and plasminogen activator inhibitor-1 activities in septic patients. World J Surg 2001, 25:660-668.
53. Kushi H, Miki T, Sakagami Y, Sato J, Saito T, Tanjoh K Hemoperfusion with an immobilized polymyxin B fiber column decreases macrophage and monocyte activity. Ther Apher Dial 2009, 13:515-519.
54. Kushi H, Nakahara J, Miki T, Okamoto K, Saito T, Tanjo K Hemoperfusion with an immobilized polymyxin B fiber column inhibits activation of vascular endothelial cells. Ther Apher Dial 2005, 9:303-307.
55. Naka T, Shinozaki M, Akizawa T, Shima Y, Takaesu H, Nasu H The effect of continuous veno-venous hemofiltration or direct hemoperfusion with polymyxin B-immobilized fiber on neutrophil respiratory oxidative burst in patients with sepsis and septic shock. Ther Apher Dial 2006, 10:7-11.
56. Nishibori M, Takahashi HK, Katayama H Specific removal of monocytes from peripheral blood of septic patients by polymyxin B-immobilized filter column. Acta Med Okayama 2009, 63:65-69.
57. Varga K, Wagner JA, Bridgen DT, Kunos G Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 1998, 12:1035-1044.
58. Wang Y, Liu Y, Sarker KP, et al. Polymyxin B binds to anandamide and inhibits its cytotoxic effect. FEBS Lett 2000, 470:151-155.
59. Staubach KH, Boehme M, Zimmermann M, Otto V A new endotoxin adsorption device in gram-negative sepsis: use of immobilized albumin with the MATISSE® adsorber. Transfus Apher Sci 2003, 29:93-98.
60. Reinhart K, Meier-Hellmann A, Beale R, et al. Open randomized phase II trial of an extracorporeal endotoxin adsorber in suspected gram-negative sepsis. Crit Care Med 2004, 32:1662-1668.
61. 2-microglobulin adsorbent column (Lixelle): the new approach for endotoxinemia. Ther Apher 2002, 6:116-118.
62. Tsuda K, Taniguchi T Effects of extracorporeal treatment with Lixelle on the mortality and inflammatory responses to endotoxin-induced shock in rats. Ther Apher Dial 2006, 10:49-53.
63. Taniguchi T, Hirai F, Takemoto Y, et al. A novel adsorbent of circulating bacterial toxins and cytokines: the effect of direct hemoperfusion with CTR column for the treatment of experimental endotoxemia. Crit Care Med 2006, 34:800-806.
64. Tsuchida K, Takemoto Y, Sugimura K, Yoshimura R, Nakatani T Direct hemoperfusion by using Lixelle column for the treatment of systemic inflammatory response syndrome. Int J Mol Med 2002, 10:485-488.
65. 2-microglobulin-selective adsorbent column eliminates inflammatory cytokines and improves pulmonary oxygenation. Ther Apher Dial 2009, 13:27-33.
66. Blomquist S, Gustafsson V, Manolopoulos T, Pierre L Clinical experience with a novel endotoxin adsorbtion device in patients undergoing cardiac surgery. Perfusion 2009, 24:13-17.
67. Kulabukhov V, Chizhov A. The use of a novel technique for adsorption of lipopolysaccharide in combined therapy of patients with severe gram negative sepsis [poster]. Proceedings of Sepsis 2008, An International Sepsis Symposium, Granada, Spain; Nov 19-22, 2008: abstract P78.
68. Ala-Kokko T, Koskenkari J, Laurila J LPS adsorber in abdominal septic shock [abstract A305]. Crit Care 2009, 13(suppl 1):P280.
69. Yaroustovsky M, Abramyan M, Popok Z, et al. Preliminary report regarding the use of selective sorbents in complex cardiac surgery patients with extensive sepsis and prolonged intensive care stay. Blood Purif 2009, 28:227-233.
70. Bengsch S, Boos KS, Nagel D, Seidel D, Inthorn D Extracorporeal plasma treatment for the removal of endotoxin in patients with sepsis: clinical results of a pilot study. Shock 2005, 23:494-500.
71. Kellum JA, Uchino S International differences in the treatment of sepsis: are they justified?. JAMA 2009, 301:2496-2497.